News release: Renishaw announces completion of the main part of a multi-centre clinical trial (docx)

File size: 105 kB Language: English

Global engineering technologies company, Renishaw, announces that its award-winning intraparenchymal drug delivery device, has played a critical role in a joint Phase 1-2 clinical study with Herantis Pharma plc, for the investigation of cerebral dopamine neurotrophic factor (CDNF) as a treatment for Parkinson's disease.

This type of file requires a viewer, freely available from Microsoft

Download file